Erlotinib, a subtype of small‐molecule EGFR tyrosine kinase inhibitors (TKIs), has been the first‐line treatment in patients suffering from EGFR‐mutant lung cancer in a number of countries.6, 8, 9. The gene discussed is EGFR; the disease is lung carcinoma.